Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 20Terminated 5Recruiting 4Active not recruiting 4Unknown 2Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 4

Conditions

Leukemia, Myeloid, Acute 17Myelodysplastic Syndromes 7Leukemia, Myelomonocytic, Chronic 4Ovarian Neoplasms 2Melanoma 2Leukemia 2Fallopian Tube Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumor 1Sarcoma, Synovial 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, T-Cell 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia, Basophilic, Acute 1Breast Neoplasms 1Blast Crisis 1

Interventions

Azacitidine 11venetoclax 8decitabine and cedazuridine drug combination 6Tacrolimus 4Decitabine 4Cyclophosphamide 4fludarabine phosphate 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Injections 3Cytarabine 3Busulfan 3Biopsy 3ruxolitinib 2itacitinib 2fludarabine 2Whole-Body Irradiation 2Vorinostat 2Specimen Handling 2Sirolimus 2Mycophenolic Acid 2Lenalidomide 2CPX-351 2veliparib 1tagraxofusp 1spartalizumab 1seclidemstat 1sabatolimab 1quizartinib 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Myelomonocytic, Chronic × Decitabine × Clear all
NCT05038592 2026-04-14

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
64 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT04980404 2026-03-30

Inqovi Maintenance Therapy in Myeloid Neoplasms

Massachusetts General Hospital

Phase 1 Active not recruiting
22 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelomonocytic, Chronic

NCT05201066 2026-01-07

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Novartis

Phase 2 Active not recruiting
33 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT04891757 2025-07-10

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

Foghorn Therapeutics Inc.

Phase 1 Active not recruiting
144 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡